LivaNova (NASDAQ:LIVN) was downgraded by research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report released on Tuesday.
Several other equities analysts have also recently weighed in on the stock. Stifel Nicolaus raised their target price on shares of LivaNova from $115.00 to $130.00 and gave the company a “buy” rating in a research note on Tuesday, July 24th. Needham & Company LLC reissued a “buy” rating and issued a $106.00 target price (up from $102.00) on shares of LivaNova in a research note on Thursday, May 31st. Zacks Investment Research raised shares of LivaNova from a “sell” rating to a “hold” rating in a research note on Wednesday, July 4th. Finally, ValuEngine raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, June 27th. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $102.67.
Shares of LIVN opened at $123.73 on Tuesday. LivaNova has a twelve month low of $67.95 and a twelve month high of $131.54. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.51 and a quick ratio of 1.08. The company has a market cap of $6.36 billion, a PE ratio of 37.38, a price-to-earnings-growth ratio of 3.77 and a beta of 0.93.
LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, August 1st. The company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.04. LivaNova had a negative net margin of 4.93% and a positive return on equity of 9.24%. The business had revenue of $287.50 million during the quarter, compared to analysts’ expectations of $278.08 million. During the same period last year, the business earned $0.93 earnings per share. The firm’s revenue was up 12.4% on a year-over-year basis. sell-side analysts expect that LivaNova will post 3.24 EPS for the current fiscal year.
In other LivaNova news, Director Daniel Jeffrey Moore sold 1,000 shares of the firm’s stock in a transaction on Monday, July 16th. The stock was sold at an average price of $102.19, for a total transaction of $102,190.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Douglas John Manko sold 2,058 shares of the firm’s stock in a transaction on Wednesday, August 15th. The shares were sold at an average price of $121.61, for a total value of $250,273.38. The disclosure for this sale can be found here. Insiders sold 5,558 shares of company stock valued at $627,103 over the last three months. 0.41% of the stock is owned by company insiders.
A number of institutional investors have recently made changes to their positions in the business. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its holdings in LivaNova by 24.9% during the 2nd quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,973 shares of the company’s stock valued at $397,000 after purchasing an additional 792 shares during the last quarter. grace capital acquired a new stake in LivaNova during the 2nd quarter valued at $100,000. Redmile Group LLC lifted its holdings in LivaNova by 15.7% during the 2nd quarter. Redmile Group LLC now owns 599,788 shares of the company’s stock valued at $59,871,000 after purchasing an additional 81,500 shares during the last quarter. Point72 Europe London LLP lifted its holdings in LivaNova by 103.2% during the 2nd quarter. Point72 Europe London LLP now owns 71,872 shares of the company’s stock valued at $7,174,000 after purchasing an additional 36,500 shares during the last quarter. Finally, Cubist Systematic Strategies LLC lifted its holdings in LivaNova by 22.2% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 2,404 shares of the company’s stock valued at $240,000 after purchasing an additional 437 shares during the last quarter. 86.92% of the stock is owned by institutional investors and hedge funds.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
Read More: Price to Earnings Ratio (PE), For Valuing Stocks
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.